Reuters logo
2 个月内
BRIEF-Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept
2017年6月1日 / 中午11点45分 / 2 个月内

BRIEF-Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept

1 分钟阅读

June 1 (Reuters) - Celgene Corp

* Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia

* Acceleron Pharma Inc - ‍companies expect to report top-line results from Phase 3 studies in mid-2018​

* Acceleron Pharma Inc - ‍medalist phase 3 trial has enrolled 210 patients with lower-risk mds​

* Acceleron Pharma Inc - ‍believe phase 3 trial has enrolled 300 patients with transfusion dependent beta-thalassemia​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below